Authorized purpose: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
Clinical role
Segmentation, volumetric quantification and PET uptake quantification
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain
Key limitation
Keep in mind: Quantitative imaging support, not a standalone diagnosis. Each module has a distinct input and validation context; values and normative percentiles should not be assumed interchangeable with other software.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain Input: DICOM 3D T1, T2-FLAIR and T2* GRE/SWI MRI and amyloid PET images.
Who uses it?Intended users: Qualified healthcare professionals, including physicians.
What does the software produce?Output: Brain-structure and lesion labels/volumes, percentile comparison to reference data, SUVR and Centiloid calculation, reports and DICOM output for DICOM workstations and PACS; comparison to prior scans is available when present.
What is its most important limitation?Key limitation: Quantitative imaging support, not a standalone diagnosis. Each module has a distinct input and validation context; values and normative percentiles should not be assumed interchangeable with other software.
Clinical takeaway. Clinical role: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
Evidence takeaway. Evidence from the reviewed source record: FDA summary describes module-specific independent validation datasets held separate from training data: 60 T1 MRI cases, 136 FLAIR cases, 30 paired MRI-PET datasets, 176 paired T1/PET scans for Centiloid classification, 100 edema-like FLAIR scans and 106 GRE/SWI scans. These are different tests, not one pooled clinical cohort.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.
Brain-structure and lesion labels/volumes, percentile comparison to reference data, SUVR and Centiloid calculation, reports and DICOM output for DICOM workstations and PACS; comparison to prior scans is available when present.
Baseline source-backed adult population retained; FDA validation describes approximately 40-80+ year old adults rather than all possible clinical use ages.
Quantitative imaging support, not a standalone diagnosis. Each module has a distinct input and validation context; values and normative percentiles should not be assumed interchangeable with other software.
FDA summary describes module-specific independent validation datasets held separate from training data: 60 T1 MRI cases, 136 FLAIR cases, 30 paired MRI-PET datasets, 176 paired T1/PET scans for Centiloid classification, 100 edema-like FLAIR scans and 106 GRE/SWI scans. These are different tests, not one pooled clinical cohort.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA summary describes module-specific independent validation datasets held separate from training data: 60 T1 MRI cases, 136 FLAIR cases, 30 paired MRI-PET datasets, 176 paired T1/PET scans for Centiloid classification, 100 edema-like FLAIR scans and 106 GRE/SWI scans. These are different tests, not one pooled clinical cohort.
The reviewed module validation reports segmentation, agreement and classification endpoints, not a single diagnostic sensitivity applicable across use cases.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-06
No single product-wide diagnostic specificity was established in the reviewed summary.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K252496 T1-SegEngine validation
DesignStandalone segmentation comparison with expert manual segmentations
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM 3D T1, T2-FLAIR and T2* GRE/SWI MRI and amyloid PET images.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed FDA summary describes DICOM input/output but does not establish the complete commercial hosting, on-premise/cloud topology or upgrade workflow.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-06 ·
Returned objects
Source context, not route validation: Brain-structure and lesion labels/volumes, percentile comparison to reference data, SUVR and Centiloid calculation, reports and DICOM output for DICOM workstations and PACS; comparison to prior scans is available when present.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Brain-structure and lesion labels/volumes, percentile comparison to reference data, SUVR and Centiloid calculation, reports and DICOM output for DICOM workstations and PACS; comparison to prior scans is available when present.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Neurophet announced on its press page and company history page that it obtained international information security certifications ISO 27001 and ISO 27701 (Korean-language pages).
Vendor-wide
Checked 2026-10-27
Vendor statement (Korean-language press release headline and history entry on the owning domain); the press page body did not render readable text on 2026-10-27 and certificates were not read. Exact-release scope is not established.
Vendor announcement positions MRI/PET quantitative analysis across Alzheimer-care evaluation; this is family context, not an independently verified outcomes claim.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-06Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored literature-index and trial-registry candidate arrays were empty and screened. This does not assert that no literature or trials exist; no unscreened study is promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, vendor announcement, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission
No public U.S. list price, installation charge or license term was identified in reviewed primary sources.
Pricing model: Not verified - checked 2026-09-06 - Exact FDA submission
Per-case, module, site and support-model terms remain unverified.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Neurophet AQUA AD Plus reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Results were Japan or Korea coverage news and vendor pages, not US coding or payment for this product. This records what was found, not that none exists.
Deployment: Not publicly available - checked 2026-09-06 - Exact FDA submission
The reviewed FDA summary describes DICOM input/output but does not establish the complete commercial hosting, on-premise/cloud topology or upgrade workflow.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-06 - Exact FDA submission
Current workflow training, reader qualification and support arrangements require vendor confirmation.
Monitoring: Not verified - checked 2026-09-06 - Exact FDA submission
Public sources reviewed do not establish site-level production monitoring, update acceptance or incident escalation.
Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, and GPi, and segment implanted leads for professional review.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.